Medpace Holdings Inc vs Opendoor Technologies Inc — how do they compare? Medpace Holdings Inc trades at $602 (market cap $16.87B), while Opendoor Technologies Inc trades at $2.32 (market cap $2.22B). The key difference: Medpace Holdings Inc is far larger — about 7.6× Opendoor Technologies Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Opendoor Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Opendoor Technologies Inc for 33 Days on average.
| MEDP | OPEN | |
|---|---|---|
Market Cap | $16.87B | $2.22B |
Volume | 207,570 | 28,705,892 |
Sector | Health | Real Estate |
52-Week High | $630.19 | $9.37 |
52-Week Low | $393.42 | $2.27 |
Typical Hold Time | 14 Days | 33 Days |
Enterprise Value | $16.48B | $3.29B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Opendoor Technologies (OPEN) trades at $2.27, showing no change in the latest session. The stock faces significant fundamental challenges with a net income margin of -46.74% and negative ROE of -196.89%, though it maintains a reasonable P/S ratio of 0.62. Recent earnings show mixed results with one beat and two misses in the last three quarters. Technical indicators signal bearish momentum with moving averages and oscillators in sell territory, while analyst sentiment remains cautious with 65% hold ratings despite a $4.92 consensus price target representing 117% upside potential.
The outlook remains challenging as the company navigates persistent losses and housing market volatility. While the mortgage expansion initiative and share repurchase program offer potential catalysts, execution risks and macroeconomic headwinds pose significant threats. The substantial gap between current price and analyst targets suggests potential upside if operational improvements materialize, but investors face substantial risk given the company's negative profitability and high debt levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →